Biomarker Solutions

News

Berlin Institute of Health (BIH) selects BioCog Consortium as a „pathfinder study“

The FP7 EU-funded BioCog Consortium (Biomarker Development for Postoperative Cognitive Impairment in the Elderly), which includes Pharmaimage GmbH as a major partner, has been selected by the Berlin Institute of Health (BIH) as a „pathfinder study“.

The BIH, which is funded by the Federal Government and the City of Berlin is a newly founded collaborative platform for translational research of the Charite – University Medicine Berlin and the Max-Delbrück Center for Molecular Medicine (Helmholtz Foundation): https://www.bihealth.org/en

Georg Winterer, Coordinator of the BioCog Consortium and CRO of Pharmaimage:

„Support from BIH is extremely helpful for the BioCog Consortium because it provides access to state-of-the art clinical research infrastructure for conducting large-scale clinical studies in a University Hospital setting. In addition, we will be able to extend our previous BioCog study protocol, now allowing additional microRNA array and metabolomic investigations.“

© PI-PharmaImage Germany GmbH 2017 | Webdesign: blickpunkt x, Köln

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.